COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial guidance for the full year 2026, reflecting stronger-than-expected performance in its ...

Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range Fagron, the leading global player in pharmaceutical compounding, today publishes its ...

First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous ...

“Completing Phase 1 and the decision by Neurosterix to progress NTX-253 into Phase 2 studies in schizophrenia patients is a significant achievement,” said Tim Dyer, CEO of Addex. “The well-designed ...

Bio Usawa Biotechnology today announced the launch of Bio Usawa Biotech Botswana (Pty) Ltd, marking an important milestone in the company’s mission to build a self-sustaining biotechnology ecosystem ...

Neo-Essentialism is not meant to replace existing schools of thought. Minimally invasive dentistry, biomimetic dentistry, adhesive dentistry, preventive care, and regenerative approaches have all ...

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic ...

Rockville, Md., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Embark Behavioral Health announced today that its intensive outpatient clinic in Rockville will relocate to a larger space in Germantown, with the ...

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes Petrelintide achieved up to 9.2% mean body ...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong growth momentum in tablet sales across regions.

IXCHIQ ® was launched in the UK in mid-2025. Due to low sales amongst travelers, Valneva has not actively distributed IXCHIQ ® in the UK for several months. As no product currently remains on the UK ...